Lifeboat Foundation

[This article is drawn from Ch. 8: “Pedagogical Love: An Evolutionary Force” in Postformal Education: A Philosophy for Complex Futures.]

“There is nothing more important in this world than radical love” as Paolo Freire told Joe Kincheloe over dinner.

- Joe Kincheloe. Reading, Writing and Cognition. 2006.

Continue reading “What’s Love got to do with Education?” »

Research on solar cells has been going on at a breakneck pace. However, with the advent of organics based cells, solar energy will be ‘greener’ than ever.

With only a few days left of 2017 we are $1,206,000 towards our $1,250,000 Winter Fundraiser goal.

Please help us reach our $1,250,000 goal by donating generously today! Remember, your support is crucial to our continued fight against age-related diseases.

Visit: http://www.sens.org/donate

Continue reading “We are almost to our final goal!” »

TOKYO — Japan’s Otsuka Pharmaceutical plans to roll out the world’s first commercial “digital pill” in the U.S. as early as next spring. The U.S. Food and Drug Administration in November green-lighted the drugmaker to produce and sell the product, Abilify MyCite.

Fan-made video animation — launch & landing of SpaceX Big Falcon Rocket (BFR); created by Reddit user Hazegrayart.

https://youtube.com/watch?v=5Sd-zLdC7qc

We live in an age of incredible technological innovation. Innovation that has the potential to do great good or great harm to society. Prince Harry, sat down with one of the most celebrated figures in Artificial Intelligence, Demis Hassabis, British artificial intelligence researcher, neuroscientist, computer game designer, entrepreneur, the co-founder and CEO of DeepMind, to discuss the responsibility that big tech firms have to ensure that change to society is positive. The Artificial Intelligence Channel.

The end of the year is approaching, and as we prepare for the celebrations for the new year, what could be better than sitting down with a warm drink and recapping 2017 in the world of rejuvenation biotechnology?

Winter kick-off

Continue reading “Looking Back at 2017: A Year in Rejuvenation Biotechnology” »

Usually, when we’ve referred to Crispr, we’ve really meant Crispr/Cas9—a riboprotein complex composed of a short strand of RNA and an efficient DNA-cutting enzyme. It did for biology and medicine what the Model T did for manufacturing and transportation; democratizing access to a revolutionary technology and disrupting the status quo in the process. Crispr has already been used to treat cancer in humans, and it could be in clinical trials to cure genetic diseases like sickle cell anemia and beta thalassemia as soon as next year.

But like the Model T, Crispr Classic is somewhat clunky, unreliable, and a bit dangerous. It can’t bind to just any place in the genome. It sometimes cuts in the wrong places. And it has no off-switch. If the Model T was prone to overheating, Crispr Classic is prone to overeating.

Even with these limitations, Crispr Classic will continue to be a workhorse for science in 2018 and beyond. But this year, newer, flashier gene editing tools began rolling off the production line, promising to outshine their first-generation cousin. So if you were just getting your head around Crispr, buckle up. Because gene-editing 2.0 is here.

Virgin Hyperloop One set a test speed record of nearly 240 miles per hour during its third phase of testing at its site in Nevada.

The company also tested a new airlock which helped transition test pods between atmospheric and vacuum conditions during a test campaign which was completed on December 15, 2017.

Continue reading “Virgin Hyperloop One just broke its speed record” »